In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Poster session 3: Pulmonary hypertension
Session

Event : Heart Failure 2017

Topic : Other

  • Session type : Poster Session
  • Date : 01 May 2017
  • Time : 10:30 - 20:00

9 presentations in this session

Residual pulmonary hypertension after endarterectomy: what remains to be clarified?

Event : Heart Failure 2017

  • Session : Pulmonary hypertension
  • Speaker : AR Almeida (Alto Estanqueiro-Jardia,PT)

Pulmonar hypertension - A strong predictor of mortality among patients admitted with acute coronary syndrome

Event : Heart Failure 2017

  • Session : Pulmonary hypertension
  • Speaker : G Abreu (Pacos De Ferreira,PT)

Pulmonary endarterectomy across borders: results of a program for chronic thromboembolic pulmonary hypertension

Event : Heart Failure 2017

  • Session : Pulmonary hypertension
  • Speaker : AR Almeida (Alto Estanqueiro-Jardia,PT)

Prevalence of prognostic factors in pulmonary hypertension

Event : Heart Failure 2017

  • Session : Pulmonary hypertension
  • Speaker : A Lescano (Quilmes,AR)

Pulmonary hypertension due to left heart disease and etiology of heart failure

Event : Heart Failure 2017

  • Session : Pulmonary hypertension
  • Speaker : MK Kaluzna-Oleksy (Poznan,PL)

Experience with macitentan in patients with pulmonary hypertension in a reference hospital

Event : Heart Failure 2017

  • Session : Pulmonary hypertension
  • Speaker : L Almenar Bonet (Valencia,ES)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are